Rosenheck R, Evans D, Herz L, Cramer J, Xu W, Thomas J, Henderson W, Charney D
VA's Northeast Evaluation Center, VA Connecticut Healthcare System, West Haven 06516-2770, USA.
Schizophr Bull. 1999;25(4):709-19. doi: 10.1093/oxfordjournals.schbul.a033412.
This study compared the time course to clinical improvement with clozapine and with conventional antipsychotic medications. A double-blind trial compared clozapine and haloperidol in patients with schizophrenia who were refractory to conventional antipsychotic medication and were hospitalized for 30 to 364 days at 15 Veteran Affairs medical centers during the year before study entry. Patients in the original study were randomly assigned to haloperidol or clozapine and followed for 12 months, at maximum tolerable doses. Patients who completed a full year of treatment with clozapine (n = 122), or with either haloperidol or another conventional antipsychotic medication (n = 123) and who also completed the 9- or 12-month assessment were included. Response to treatment was defined as 20 percent improvement on standard scales of symptoms and quality of life at the latter of the 9- or 12-month interviews. More patients assigned to clozapine achieved 20 percent improvement in symptoms at each followup. Among patients who did not improve at 6 weeks, 3 months, or 6 months, there were no significant differences between clozapine and comparison patients in outcomes at 1 year. Among patients who did improve, maintenance of that improvement also did not differ between the groups at 1 year on symptom measures. Maintenance of improvement in quality of life at 1 year was significantly greater for clozapine patients who had improved at 6 months (p < 0.04). Significant differential symptom response to clozapine occurred exclusively during the first 6 weeks of treatment.
本研究比较了氯氮平和传统抗精神病药物临床改善的时间进程。一项双盲试验在15家退伍军人事务医疗中心,对在研究入组前一年因对传统抗精神病药物难治而住院30至364天的精神分裂症患者,比较了氯氮平和氟哌啶醇。原研究中的患者被随机分配至氟哌啶醇或氯氮平组,并以最大耐受剂量随访12个月。完成一整年氯氮平治疗的患者(n = 122),或完成氟哌啶醇或其他传统抗精神病药物治疗的患者(n = 123),且同时完成9个月或12个月评估的患者被纳入。治疗反应定义为在9个月或12个月访谈后期,症状和生活质量标准量表上改善20%。在每次随访时,更多分配至氯氮平组的患者症状改善达到20%。在6周、3个月或6个月时未改善的患者中,氯氮平组和对照组患者在1年时的结局无显著差异。在改善的患者中,两组在1年时症状测量的改善维持情况也无差异。在6个月时已改善的氯氮平组患者中,1年时生活质量改善的维持情况显著更好(p < 0.04)。对氯氮平显著的症状差异反应仅发生在治疗的前6周。